NCT05435027 - Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV) | Biotech Hunter

Enrollment

342

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

March 6, 2024

Study Completion Date

March 6, 2024

Conditions

COVID-19SARS-CoV-2

Interventions

DRUG

GRT-R912, samRNA-Spikebeta-TCE11

IM injection of GRT-R912. Doses will be decided after safety review of Part A.

DRUG

GRT-R914, samRNA-Spikebeta-TCE9

"Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A."

DRUG

GRT-R918, samRNA-SpikeOmicron-N-TCE11

IM injection of GRT-R918. Doses will be decided after safety review of Part A.

Trial Locations (4)

Unknown

Newtown Clinical Research Centre, Johannesburg

WITS RHI Shandukani Research Centre, Johannesburg

Wits Vaccines & Infections Diseases Analytics (VIDA) Research Unit, Johannesburg

Setshaba Research Center, Pretoria